000864473 001__ 864473
000864473 005__ 20230215201828.0
000864473 0247_ $$2doi$$a10.1080/02688697.2019.1639615
000864473 0247_ $$2ISSN$$a0268-8697
000864473 0247_ $$2ISSN$$a1360-046X
000864473 0247_ $$2Handle$$a2128/30696
000864473 0247_ $$2pmid$$a31407920
000864473 0247_ $$2WOS$$aWOS:000480905300001
000864473 037__ $$aFZJ-2019-04251
000864473 082__ $$a610
000864473 1001_ $$0P:(DE-HGF)0$$aSchmitz, Ann Kristin$$b0$$eCorresponding author
000864473 245__ $$aDiagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine ( 18 F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients
000864473 260__ $$aLondon [u.a.]$$bTaylor & Francis$$c2021
000864473 3367_ $$2DRIVER$$aarticle
000864473 3367_ $$2DataCite$$aOutput Types/Journal article
000864473 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1676461265_10240
000864473 3367_ $$2BibTeX$$aARTICLE
000864473 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000864473 3367_ $$00$$2EndNote$$aJournal Article
000864473 520__ $$aObjective: Vaccination therapy using tumour antigen-loaded, autologous dendritic cells (DC) is a promising therapeutic approach alongside standard treatment for glioblastoma (GBM). However, reliable diagnostic criteria regarding therapy monitoring are not established. Here, we analysed the impact of additional 18F-fluoroethyl-tyrosine positron emission tomography (18F-FET PET) imaging following DC vaccination therapy.Methods: We analysed data of GBM patients who received DC vaccination therapy. Following MRI diagnosis of tumour recurrence, additional static and dynamic 18F-FET PET imaging was performed. Vaccination was performed five times by intradermal injections, either weekly between concomitant radio/-chemotherapy and intermittent chemotherapy or after tumour recurrence, before re-radiation therapy. MRI and 18F-FET PET results were compared and correlated with clinical data.Results: Between 2003 and 2016, 5 patients were identified who received DC vaccination and 18F-FET PET imaging (1 female/4 males; mean age: 44 ± 14 y). 3/5 patients showed congruent results of tumour progression. In three patients 18F-FET PET indicated treatment related changes, which was in contrast to MRI findings that indicated tumour progression. In these patients 18F-FET PET results could be confirmed by either neuropathological diagnosis or according to the RANO criteriaConclusions: Despite the small patients number our results indicate an additional impact of 18F-FET PET for monitoring outcome following vaccination therapy.
000864473 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000864473 588__ $$aDataset connected to CrossRef
000864473 7001_ $$0P:(DE-HGF)0$$aSorg, Rüdiger V.$$b1
000864473 7001_ $$0P:(DE-Juel1)131627$$aStoffels, Gabriele$$b2$$ufzj
000864473 7001_ $$0P:(DE-HGF)0$$aGrauer, Oliver M.$$b3
000864473 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b4$$ufzj
000864473 7001_ $$0P:(DE-HGF)0$$aSteiger, Hans-Jakob$$b5
000864473 7001_ $$0P:(DE-HGF)0$$aKamp, Marcel A.$$b6
000864473 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b7$$ufzj
000864473 7001_ $$0P:(DE-Juel1)165921$$aSabel, Michael$$b8
000864473 7001_ $$0P:(DE-HGF)0$$aRapp, Marion$$b9
000864473 773__ $$0PERI:(DE-600)1499131-7$$a10.1080/02688697.2019.1639615$$gp. 1 - 7$$n6$$p736-742$$tBritish journal of neurosurgery$$v35$$x1360-046X$$y2021
000864473 8564_ $$uhttps://juser.fz-juelich.de/record/864473/files/Schmitz%20Postprint%20BJN%202019.pdf$$yPublished on 2019-08-13. Available in OpenAccess from 2020-08-13.
000864473 8564_ $$uhttps://juser.fz-juelich.de/record/864473/files/Schmitz%20Postprint%20BJN%202019.pdf?subformat=pdfa$$xpdfa$$yPublished on 2019-08-13. Available in OpenAccess from 2020-08-13.
000864473 909CO $$ooai:juser.fz-juelich.de:864473$$popenaire$$pdnbdelivery$$pdriver$$pVDB$$popen_access
000864473 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich$$b2$$kFZJ
000864473 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b4$$kFZJ
000864473 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b7$$kFZJ
000864473 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000864473 9141_ $$y2022
000864473 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000864473 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000864473 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
000864473 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J NEUROSURG : 2017
000864473 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000864473 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000864473 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000864473 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000864473 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000864473 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000864473 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000864473 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000864473 920__ $$lyes
000864473 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000864473 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000864473 980__ $$ajournal
000864473 980__ $$aVDB
000864473 980__ $$aI:(DE-Juel1)INM-3-20090406
000864473 980__ $$aI:(DE-Juel1)INM-4-20090406
000864473 980__ $$aUNRESTRICTED
000864473 9801_ $$aFullTexts